Psoriasis is a chronic immune-mediated inflammatory skin disease accompanied by the gradual involvement in the pathological process not only the skin and mucous membranes but also the internal organs: the musculoskeletal system, nervous system, cardiovascular system, gastrointestinal tract and urinary system.
OBJECTIVE
To systematize the main problems of medical care organization and drug provision for patients with psoriasis using data from calculating the economic burden of the disease on the budget of the Russian Federation and assessing the quality and availability of high-tech medical care.
MATERIAL AND METHODS
In the work, the data from official statistics was used. It was analyzed the published data on the prevalence of psoriasis in the Russian Federation, the impact on the health care budget of certain treatment regimens with specific drugs. The results of expert interviews with the professional community, chief freelance specialists at the federal and regional levels (dermatologist-venerologists), healthcare organizers, representatives of the authorities’ management of the health care system in the constituent entities of the Russian Federation were accounted.
RESULTS
There were 356 069 patients with psoriasis in Russia in 2018 that correspond to a prevalence rate of 242.4 cases per 100 000 population. The economic burden with the current level of provision of genetically engineered biological preparations (GEBP) for patients with psoriasis amounted to 90.48 billion rubles per year (260.79 thousand rubles per 1 patient per year) where 22.7 billion rubles are direct medical costs. The volume of underfunding for providing patients with psoriasis with GEBP 3.94 billion rubles per year.
CONCLUSION
The annual economic burden of psoriasis is comparable to the costs of other socially significant diseases like lung cancer, breast cancer, inflammatory bowel diseases, and reflects the high socio-economic importance of psoriasis for the State. The main problems of medical care organization and drug provision for patients with psoriasis are 1) discrepancy between the data of official statistics and the real values of the psoriasis prevalence in the Russian Federation due to the lack of a unified federal register of patients with psoriasis; 2) insufficient provision of GEBP for all patients with psoriasis due to limited funding.
